KRAS Inhibition Activates an Actionable CD24 "Don't Eat Me" Signal in Pancreatic Cancer
Abstract:
KRAS G12C inhibitors (G12Ci) have produced encouraging, albeit modest and transient, clinical benefit in pancreatic ductal adenocarcinoma (PDAC). Identifying and targeting resistance mechanisms to G12Ci treatment is therefore crucial. To better understand the function of KRAS G12C and possible G12Ci bypass mechanisms, we developed an autochthonous KRAS G12C - driven PDAC model. Compared to the classical KRAS G12D PDAC model, the G12C model exhibits slower tumor growth, yet similar histopathological and molecular features. Aligned with clinical experience, G12Ci treatment of KRAS G12C tumors produced modest impact despite stimulating a 'hot' tumor immune microenvironment. Immunoprofiling revealed that CD24, a 'don't eat me' signal, is significantly upregulated on cancer cells upon G12Ci treatment. Blocking CD24 enhanced macrophage phagocytosis of cancer cells and significantly sensitized tumors to G12Ci treatment. Similar findings were observed in KRAS G12D -driven PDAC. Together, this study reveals common and distinct oncogenic KRAS allele-specific biology and identifies a clinically actionable adaptive mechanism that may improve the efficacy of oncogenic KRAS inhibitor therapy in PDAC.
Significance:
Generation of an autochthonous KRAS G12C -driven pancreatic cancer model enabled elucidation of specific effects of KRAS G12C during tumor development, revealing CD24 as an actionable adaptive mechanism in cancer cells induced upon KRAS G12C inhibition.
Insights
Targeting KRAS G12C in pancreatic cancer shows modest benefit. Blocking CD24, a
Area of Science:
- Oncology
- Cancer Biology
- Immunology
Background:
- KRAS G12C inhibitors offer limited clinical benefit in pancreatic ductal adenocarcinoma (PDAC), necessitating research into resistance mechanisms.
- Developing faithful preclinical models is essential for understanding PDAC tumor biology and identifying therapeutic vulnerabilities.
- Oncogenic KRAS alleles exhibit distinct biology, impacting therapeutic strategies in PDAC.
Conclusions:
- CD24 is an actionable adaptive resistance mechanism in PDAC treated with KRAS G12C inhibitors.
- Combining KRAS inhibitors with CD24 blockade represents a promising strategy to improve therapeutic efficacy in PDAC.
- This study elucidates common and distinct KRAS allele-specific biology, offering insights into PDAC treatment.
More Related Videos
06:21Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
